Precigen Inc

-0.01 (-0.70%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)362.78M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$1.98 Million
Adjusted EPS-$0.08
See more estimates
10-Day MA$1.43
50-Day MA$1.47
200-Day MA$1.36
See more pivots

Precigen Inc Stock, NASDAQ:PGEN

20358 Seneca Meadows Parkway, Germantown, Maryland 20876
United States of America
Phone: +1.301.556.9900
Number of Employees: 209


Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.